EN | RU
EN | RU

Help Support

Back

Novel COVID-19 vaccine SPUTNIK V authorized in 44 countries

Novel COVID-19 vaccine SPUTNIK V authorized in 44 countries Novel COVID-19 vaccine SPUTNIK V authorized in 44 countries
Novel COVID-19 vaccine SPUTNIK V authorized in 44 countries Novel COVID-19 vaccine SPUTNIK V authorized in 44 countries

What's new?

SPUTNIK V receives approval to manage patients suffering from coronavirus disease (COVID-19).

As per the notification on 19 February 2021, the Russian Direct Investment Fund (RDIF) announced the approval of the Russian Sputnik V vaccine to fight severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by the Ministry of Health of the Republic of San Marino (the oldest state in Europe).

The vaccine was granted approval under the emergency use authorization procedure. San Marino has successfully become the 30th country in the world to give approval to this vaccine. SPUTNIK V is one of the world's top three COVID-19 vaccines regarding the number of approvals published by government regulators.

Laos has become the 44th country in the world to register Sputnik V. This vaccine is extensively recognized globally by regulatory authorities and medical professionals that is attributed to its high efficacy, safety, and affordability.

Sputnik V has numerous pivotal benefits. As confirmed by the data published in Lancet, the efficacy of Sputnik V was shown to be 91.6%. This vaccine offers complete protection against severe coronavirus cases and is one of only three vaccines in the world that has demonstrated superior effectiveness of over 90%. Sputnik V is based on a verified and widely-analyzed platform of human adenoviral vectors that lead to the common cold and have been around for numerous years.

This vaccine utilizes 2 distinct vectors for the two shots in the vaccination course. It offers a longer duration immunity compared to vaccines utilizing a similar delivery mechanism for both shots. The effectiveness, safety, and paucity of the negative long-term impact of adenoviral vaccines have been demonstrated by more than 250 studies over 2 decades. This vaccine does not cause strong allergies.

The storage temperature of the vaccine at +2+8 C. This indicates that the storage of this coronavirus vaccine is possible in a conventional refrigerator. There is no requisition for investing in extra cold-chain infrastructure. Furthermore, the cost of this vaccine is less than $10 per shot, thus making it a cost-effective agent.

Source:

Sputnik V

Article:

SPUTNIK V AUTHORIZED IN 30 COUNTRIES

Comments (0)

Recommendations

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru
Try: